<qa>  What is the name of the PARTICIPANTS that are PARTICIPANTEFFECTS OF SWITCHING FROM ATRIPLATM EFAVIRENZ, TENOFOVIR, EMTRICITABINE TO MK-1439A DORAVIRINE, TENOFOVIR, LAMIVUDINE IN VIROLOGICALLY-SUPPRESSED PARTICIPANTS MK-1439A-028: 